清肺解毒消痤方加减联合红、蓝光治疗脓疱型痤疮临床研究

 目的 观察清肺解毒消痤方加减口服和面膜外用并联合红、蓝光照射治疗脓疱型痤疮的效果.方法 将88例脓疱型痤疮患者分为2组:治疗组46例,予以清肺解毒消痤方加减口服和面膜外用并联合红、蓝光照射;对照组42例,仅予以清肺解毒消痤方加减口服和面膜外用,6周后进行疗效评定与对比.结果 治疗组痊愈率80.43％,总有效率93.47％;对照组痊愈率和总有效率分别为59.52％,78.57％.二者比较差异均有统计学意义(x2 =4.61,P＜o.05;x2=4.14,P＜ 0.05).结论 清肺解毒消痤方加减口服和面膜外用并联合红、蓝光照射治疗脓疱型痤疮有较好疗效,且操作简便,不良反应少.     

NB-UVB联合他扎罗汀凝胶外用治疗中重度寻常型银屑病疗效观察

目的观察窄谱中波紫外线(NB-UVB)联合他扎罗汀凝胶外用治疗寻常型银屑病的疗效及安全性。方法对50例中重度患者采用NB-UVB每周3次照射配合0.05%他扎罗汀凝胶每晚1次外用,共治疗8周,用PASI积分评价疗效。结果 治疗开始后1~2周出现疗效,随着治疗时间的延长,有效率逐渐提高,疗程结束时治愈率92%,有效率达100%,8例发生皮肤刺激反应,占16%。结论 NB-UVB照射联合他扎罗汀凝胶外用治疗寻常型银屑病具有良好疗效及安全性。     

蒂珂清痘净颜护肤品联合红蓝光治疗痤疮疗效观察

目的评估蒂珂(Dermal Quotient,D-Q)清痘净颜护肤品联合红蓝光发光二极管(light-emitting diode,LED)痤疮治疗仪治疗痤疮的临床疗效和安全性。方法将60例Ⅰ～Ⅲ级痤疮患者随机分为两组。DQ-LED组给予D-Q清痘净颜护肤品联合红蓝光治疗,LED组仅予红蓝光治疗。每周照射2次,治疗间隔3天,连续治疗4周。在第4周和第8周分别评估其疗效。结果第4周时,DQ-LED组和LED组有效率分别为86.67%和60.00%,两组差异有统计学意义(P<0.05)。第8周时,DQLED组和LED组有效率分别为90.00%和50.00%,两组差异有统计学意义(P<0.05)。第8周时,DQ-LED组PillsburyⅠ级痤疮患者全部痊愈或显效,PillsburyⅡ级患者痊愈或显效的例数增加。结论 D-Q清痘净颜护肤品联合红蓝光照射是治疗痤疮的有效方法,D-Q清痘净颜护肤品对于轻、中度痤疮的疗效更佳,痤疮好转后继续使用D-Q清痘净颜护肤品有助于维持治疗效果。     

强脉冲激光治疗寻常性痤疮的近期疗效观察

目的 观察420 nm脉冲强激光治疗Ⅰ～Ⅲ级寻常性痤疮的疗效.方法 Ⅰ～Ⅲ级痤疮患者118例,随机分为治疗组60例,对照组58例.治疗组使用420 nm强脉冲激光治疗,对照组外用甲硝唑凝胶治疗.分别记录治疗前及治疗后第1、2、4和8周时粉刺、丘疹及脓疱的数目变化,并对结果进行统计和评估.结果 治疗后1、2、4和8周有效率治疗组分别为33.3%、56.7%、75.0%和83.3%,对照组分别为17.4%、37.9%、58.6%和62.1%.两组疗效差异有显著意义(P＜0.05).结论 420nm强脉冲激光治疗Ⅰ～Ⅲ级痤疮,可以明显降低痤疮的炎性损害,有效消除粉刺、丘疹及脓疱等皮损,治疗后患者皮肤柔嫩、光滑、弹性增强.     

夫西地酸乳膏联合阿达帕林凝胶治疗寻常痤疮的疗效

 目的 探讨夫西地酸乳膏联合阿达帕林凝胶治疗寻常痤疮的疗效。方法 选择武警黑龙江总队医院诊治的寻常痤疮患者110例,随机分为对照组和观察组,每组各55例。对照组单独应用阿达帕林凝胶治疗,观察组联合应用夫西地酸乳膏与阿达帕林凝胶,两组均持续治疗4周。比较两组治疗后皮损数量、不良反应、复发率等。结果 治疗4周后,与对照组相比,观察组炎性皮损、非炎性皮损个数明显减少,差异有统计学意义(P＜0.05),两组治疗后不良反应差异无统计学意义。治疗后6个月,观察组的复发率3.64%(2/55)低于对照组14.55%(8/55),差异有统计学意义(P＜0.05)。结论 夫西地酸乳膏联合阿达帕林凝胶治疗寻常痤疮,可明显改善皮损情况,安全性较高,复发率低。     

420nm强脉冲光与红蓝光治疗炎症性痤疮的疗效比较

目的评价420nm强脉冲光及红蓝光治疗炎症性痤疮的临床疗效。方法炎症性痤疮患者60例,分为两组：A组30例患者,采用420nm强脉冲光治疗;B组30例患者,采用红蓝光治疗。每周治疗2次,治疗4周后评价总疗效。结果治疗后4周,A组有效率为96．7％,B组有效率为73．3％,经χ2检验,A组的有效率明显高于B组（P〈0．05）。结论420nm强脉冲光在治疗炎症性痤疮方面比红蓝光疗效好。     

外用氯柳酊治疗寻常性痤疮疗效观察

目的：观察外用氯柳酊治疗寻常性痤疮的临床疗效。方法：选择寻常性痤疮225例,随机分为观察组120例和对照组105例。对照组给予常规口服四环素片、维生素B6和雷尼替丁联合治疗;观察组在上述治疗基础上,同时外用自制氯柳酊液。治疗1个月后进行疗效评定,比较两组疗效。结果：观察组痊愈65例,好转44例,无效11例;总有效率90.8%。对照组痊愈36例,好转43例,无效26例;总有效率75.2%。两组总有效率比较,差异显著（P〈0.05）。结论：外用氯柳酊液治疗寻常性痤疮,疗效较好。     

半导体激光联合外用药物治疗湿疹的疗效观察

目的 观察半导体激光结合外用药物治疗急慢性湿疹的疗效.方法 急慢性湿疹患者58例,随机分为两组,治疗组采用波长810 nm半导体激光照射联合外用皮质激素类药物治疗,对照组以湿敷或外用激素类药物治疗.结果 急慢性湿疹的有效率比较,治疗组优于对照组,患者未见不良反应.结论 半导体激光照射联合外用药物治疗急慢性湿疹疗效好,安全性高,具有较好的临床应用价值.     

红蓝光痤疮光动力治疗仪治疗面部痤疮

正目的:观察红蓝光痤疮光动力治疗仪治疗面部痤疮的临床疗效。方法:2014年10月至2015年8月,寻常型痤疮患者106例,男性45例,女性61例;年龄18~40岁,平均26岁;病程3个月~10年,平均2.1年。采用红蓝光痤疮治疗仪治疗,波长(415±5)μm。结果:106例患者,痊愈9例(8.3%),显效82例(75.9%),改善14例(12.9%),无效3例(2.7%),总有效率84.0%。     

臭氧水疗联合红光以及甲硝唑凝胶治疗玫瑰痤疮的临床疗效和安全性研究

目的探讨臭氧水疗联合红光治疗丘疹脓疱型和毛细血管扩张型玫瑰痤疮的临床疗效和安全性。方法丘疹脓疱型和红斑毛细血管扩张型玫瑰痤疮患者98例,随机分为两组,治疗组患者50例,采用臭氧水疗联合红光以及甲硝唑凝胶治疗;对照组患者48例,采用红光联合甲硝唑凝胶治疗。红光治疗能量密度40～60 J/cm~2,每次照射时间20 min,隔日1次,每周治疗3次。甲硝唑凝胶外涂,每日2次。臭氧水疗,每间隔1d治疗1次。治疗后2、4和6周观察两组疗效和不良反应。结果两组患者治疗后2、4、6周有效率分别为治疗组28.0%、58.0%、78.0%;对照组18.8%、35.4%、54.2%。两组患者治疗后2周疗效比较,差异无统计学意义(P0. 05),治疗后4和6周的疗效比较,差异具有统计学意义(P均0.05);两组治疗后丘疹脓疱数目、红斑血管扩张评分比较,差异具有统计学意义(P均0. 05)。两组患者不良反应主要为面部治疗后一过性刺激不适,不影响继续治疗,未见严重的不良反应。结论臭氧水疗是一种安全、环保、有效的方法 ,臭氧水疗联合红光照射治疗有助于缓解玫瑰痤疮患者症状,丰富了玫瑰痤疮的治疗手段。     

维胺酯乳膏和米诺环素联合治疗寻常性痤疮100例临床疗效观察

目的探讨维胺酯乳膏和米诺环素联合用药在寻常性痤疮临床治疗中的疗效和应用价值。方法100例寻常性痤疮病人应用维胺酯乳膏和米诺环素联合治疗,观察皮疹的消退情况及其副作用。结果100例患者经过两个疗程的治疗,有效率为92%。结论维胺酯乳膏和米诺环素联合治疗寻常性痤疮,效果明显,副作用较少,值得临床推广应用。     

自制阿螺A微乳膏治疗痤疮的疗效观察

目的观察阿螺A微乳膏治疗痤疮的临床疗效。方法 256例患者随机分为:治疗组138例,外用阿螺A微乳膏;对照组118例,外用异维A酸凝胶,疗程8周。结果治疗组、对照组总有效率分别为90%、69%,两组差异有显著统计学意义(P<0.01)。结论阿螺A微乳膏治疗痤疮疗效显著、安全性高。     

强脉冲光治疗寻常型痤疮的疗效

目的评价强脉冲光治疗寻常型痤疮的疗效及其安全性.方法寻常型痤疮患者50例,其中轻度患者16例,中度患者34例.以ClearTouchTM丝柔光子痤疮治疗仪行强脉冲光治疗,每周2次,8次为一个疗程.治疗前后对皮损拍照并计数各类皮损数目,严格记录每次治疗后皮损变化及不良反应.以治疗后炎性皮损减少百分率评价疗效,并观察其安全性.结果总有效率为72.0%,其中轻、中度患者的总有效率分别为93.8%和61.8%.除一过性红斑外,未发现其他不良反应.结论强脉冲光治疗轻、中度寻常型痤疮疗效显著,疗程短、无痛苦、安全性高.     

中药联合光疗治疗寻常型银屑病的临床疗效观察

比较单纯中药和中药结合低强度窄波中波紫外光(low intensity narrow-band ultraviolet B, LUVB)和低强度810 nm半导体激光(low intensity 810 nm diode laser irradiation, LIL)对寻常型银屑病的临床疗效。从2007年3月至2010年3月的三年间,将186例寻常型银屑病患者随机分为治疗组96例和对照组90例,分别采用中药结合LUVB与LIL和单纯中药治疗3个月。治疗组痊愈39例(40.63 %),显效42例(43.75 %),有效4例(13.54 %),无效2例(2.09 %),总有效率达到了97.91 %。对照组痊愈18例(20.00 %),显效20例(22.22 %),有效23例(25.56 %),无效29例(32.22 %),总有效率达到了67.8 %。结果表明,中药联合LUVB和LIL这种新的治疗方案对寻常型银屑病的治疗优于单纯中药治疗,具有相对疗程短,疗效确切,治愈率高,复发率低,安全性好等特点,适宜基层医院推广应用。     

A new LED device used for photodynamic therapy in treatment of moderate to severe acne vulgaris

ObjectiveThis study investigated the efficacy and safety of a newly designed LED device used in photodiagnosis and photodynamic therapy of moderate to severe acne vulgaris in Chinese patients.MethodsForty-six patients with moderate to severe facial acne showing high degrees of fluorescence by ultraviolet light examination were illuminated during ALA-PDT with two wavelengths of light (543–548 nm, and 630 ± 6 nm, respectively) after 2 h of incubation with ALA. Each patient received treatment once every 30 days for two or three sessions. Two independent investigators assigned an acne severity score at baseline, one week after each treatment, as well as 4, 8, and 12 weeks after the completion of treatment. Adverse effects were recorded during and after each treatment. All patients rated their satisfaction with the results of treatment at a 12-week follow up visit.ResultsThe ALA-PDL treatment regimen showed an overall effectiveness rate of 89.13% (41/46 patients). Some degree of clinical efficacy was seen in 71.42%, 86.67%, and 95.83% of patients with grades IV, V, and VI acne, respectively, and the rate of clinical effectiveness increased with increasing acne severity. When compared with baseline scores, significant reductions in acne scores were obtained at 8, and 12 weeks after completion of treatment. Maximum efficacy was shown at the 12 week follow up. No severe adverse events were observed.ConclusionALA-PDT administered with the newly designed LED device was an effective treatment for moderate to severe acne vulgaris, and side effects were mild and reversible.     

Efficacy and therapeutic reactions of tri-needle-pretreatment combined with painless ALA-PDT for the treatment of moderate-to-severe acne vulgaris: A randomized controlled trial

Background: Our clinical experience suggests that pretreatment of the original lesions may be crucial for enhancing the efficacy of 5-aminolevulinic acid-photodynamic therapy (ALA-PDT) in moderate-to-severe acne vulgaris. We performed this randomized controlled trial (RCT) to validate this observation.Methods: Efficacy and therapeutic reactions between tri-needle-pretreatment with ALA-PDT (TP-PDT) and conventional ALA-PDT without pretreatment (NP-PDT) were compared. In TP-PDT group, tri-needle-pretreatment was performed using comedone extractors, fire needles, or plum-blossom needles, according to the lesion type. In the TP-PDT group, 5% ALA cream was applied to lesions 30 min before illumination (LED red light: 633±10 nm, 40 mW/cm², 150 J/cm²). In the NP-PDT group, 5% ALA cream was applied 1 h before illumination (60 mW/cm², 72 J/cm²). Patients underwent four sessions, at 1-week intervals. The efficacy was evaluated as the proportion of patients achieving a remarkable effective rate, based on the reduction in the number of lesions. A numeric rating scale was used to assess the severity of pain, erythema, and edema.Results: Forty-eight patients completed the trial. The proportion of remarkable effective rate was significantly greater and the pain score was significantly lower for the TP-PDT than NP-PDT group. The edema score was significantly higher for the TP-PDT than NP-PDT group. There was no difference in erythema scores between the two groups.Conclusion: The tri-needle-pretreatment can improve the efficacy of ALA-PDT, without an increase in pain, for the treatment of moderate-to-severe acne vulgaris. These qualities make the TP-PDT a promising gold standard pretreatment for ALA-PDT for acne vulgaris.     

5-氨基酮戊酸光动力疗法治疗寻常痤疮的临床观察

目的观察5-氨基酮戊酸光动力疗法(ALA-PDT)治疗寻常痤疮的安全性及有效性。方法将90例中重度痤疮患者随机单盲分为两组:治疗组45例,给予ALA-PDT治疗,1次/10 d,共治疗2～4次;对照组45例,口服异维A酸胶囊,每次10 mg,2次/d,共治疗40 d。在治疗的第10、20、30及40天对两组患者进行疗效判断和比较,同时,记录治疗过程中出现的不良反应。结果治疗组患者经过2～4次治疗后,总有效率为97.8%;对照组治疗结束时总有效率为77.8%,治疗组疗效明显优于对照组(P<0.01)。另外,治疗组复发程度明显低于对照组,且病情控制时间明显延长。治疗组的所有皮损,包括粉刺、丘疹、脓疱、囊肿、结节等均比对照组明显减少。结论 ALA-PDT治疗中重度痤疮的疗效明显优于口服异维A酸胶囊,是一种简单、高效、不良反应轻微的治疗中重度寻常痤疮的新方法。